The renewable energy sector is ramping up in a major way, but a host of infrastructure issues still need to be solved. One is that supply at times now outstrips demand, but there’s no way to store excess power. Turning it into an easy-to-store, energy-rich source like methane could solve the problem. A pivotal aspect of power-to-gas’ technology harnesses some tiny helpers usually found in some of the most extreme regions on the planet.
ArgenX reports hints to efficacy of ARGX-113 in generalised myasthenia gravis
Latest NewsDutch llama antibody specialist ArgenX met the safety endpoint in a Phase II trial with ARGX 113 (efgartigimod), a first-in-class antibody that lowers pathogenic levels of IgG, in patients with the autoimmune disease myasthenia gravis.
Ortho markets predictive heart failure re-hospitalisation test
Latest NewsIn vitro diagnostics leader Ortho Clinical Diagnostics (Raritan, US) expands his assay portfolio with Sphingotec’s first-in-class biomarker test that predicts residual edema and re-hospitalization in patients with congestive heart failure.
Hot guys in the pool rescue sustainability
BackgroundThe renewable energy sector is ramping up in a major way, but a host of infrastructure issues still need to be solved. One is that supply at times now outstrips demand, but there’s no way to store excess power. Turning it into an easy-to-store, energy-rich source like methane could solve the problem. A pivotal aspect of power-to-gas’ technology harnesses some tiny helpers usually found in some of the most extreme regions on the planet.
Advicenne raised a €27m IPO on Euronext Paris
Latest NewsFrench based Advicenne has raised a €27m IPO on Euronext Paris, to develop paediatric-friendly therapeutics for the treatment of orphan renal and neurological diseases.
Researchers create druggable “love hormone”
Latest NewsA European-Australian team of researchers has created a synthetic version of oxytocin that does not show the off-target effects mediated by its chemical analogon vasopressin.
Microsart® RESEARCH Bacteria
ProductsRapid detection of total bacteria within 2½ h.
Need a contemporary manufacturing strategy?
BackgroundConsidering the high development costs of medications and the time invested before a drug goes from discovery to market, it is critical to develop not only a solid drug development strategy, but a contemporary manufacturing strategy as well. A parallel development strategy could be one possible approach.
FDA approves pan-tumour genomic profiling assay
Latest NewsRoche company Foundation Medicine Inc. (FMI) has been granted FDA approval for a diagnostic multiplex tumour profiling assay, which identifies a broad range of tumour markers in one single measurement.
Sanofi Pasteur ends Clostridium difficile vaccine programme
Latest NewsThe decision of the vaccine arm of French drug giant Sanofi was based on an independent interim analysis of a pivotal Phase III study enroling up to 16,500 people at risk of Clostridium difficile infection (CDI) for vaccination with the jab that has FDA Fast Track designation.
A suited approach to rare disease trials
OpinionOPIS Accelerated approval for orphan drugs and the possibility to have market authorisation
after a successful Phase II trial have made research in rare diseases more attractive to sponsors.
However, challenges and uncertainties remain numerous and designing scientifi cally robust,
patient-centered trials requires proper conceptualisation.